tradingkey.logo

Mangoceuticals surges on strong sales of injectable testosterone therapy

ReutersFeb 20, 2026 10:54 AM

Shares of telehealth platform Mangoceuticals MGRX.O rise 43% to 51 cents premarket

Co says its new $99/month injectable testosterone therapy plan saw sales jump 336% month‑over‑month since mid‑December

MGRX says it also cut its customer acquisition costs by more than half

Mangoceuticals expects testosterone therapy to become its main growth driver

In 2025, MGRX plunged 70%

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI